An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis

Summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.

Timeline

Start

2015-12-15

Primary completion

2017-03-28

Completion

2018-07-17

Outcome

Met primary endpoint

registry Placebo vs Guselkumab 100 mg; p <0.001; Mean Difference (Final Values) -7.69 (95% CI -11.000 to -4.383) NCT02641730 ↗

registry Placebo vs Guselkumab 200 mg; p = 0.017; Mean Difference (Final Values) -4.11 (95% CI -7.468 to -0.748) NCT02641730 ↗

Publications

• Terui T, Kobayashi S, Okubo Y, Murakami M, Zheng R, Morishima H, Goto R, Kimura T. Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2019 Oct 1;155(10):1153-1161. doi: 10.1001/jamadermatol.2019.1394.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Guselkumab	Monoclonal antibody	100 mg	Subcutaneous
Subject	Guselkumab	Monoclonal antibody	200 mg	Subcutaneous

Indications